Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers. The company is also developing MCLA-117 that is in Phase I clinical trial for the treatment of patients with acute myeloid leukemia; and MCLA-158, which is in a Phase I clinical trial for treating metastatic colorectal cancer. In addition, its preclinical development stage bispecific antibody candidates include MCLA-145, which is being developed in collaboration with Incyte Corporation; and other preclinical candidates in various stages of development. Merus N.V. has collaboration with the Integral Molecular for discovering MAbs against structurally complex proteins; and Lipoparticles, virus-like particles displaying high concentrations of membrane proteins. The company was founded in 2003 and is headquartered in Utrecht, the Netherlands.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MRUS
Previous Symbol
CUSIPN/A
Phone31-0-30-253-8800
Debt
Debt-to-Equity RatioN/A
Current Ratio6.38
Quick Ratio6.38
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$15.36 million
Price / Sales18.08
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.79 per share
Price / Book4.40
Profitability
EPS (Most Recent Fiscal Year)($4.29)
Net Income$-82,610,000.00
Net Margins-178.79%
Return on Equity-67.34%
Return on Assets-23.01%
Miscellaneous
Employees83
Outstanding Shares22,630,000
Market Cap$281.90 million
OptionableNot Optionable
Merus (NASDAQ:MRUS) Frequently Asked Questions
What is Merus' stock symbol?
Merus trades on the NASDAQ under the ticker symbol "MRUS."
When is Merus' next earnings date?
What price target have analysts set for MRUS?
2 brokerages have issued 12-month price targets for Merus' stock. Their forecasts range from $28.00 to $34.00. On average, they expect Merus' share price to reach $31.00 in the next year. This suggests a possible upside of 152.6% from the stock's current price. View Analyst Price Targets for Merus.
What is the consensus analysts' recommendation for Merus?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merus in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Merus.
Has Merus been receiving favorable news coverage?
Press coverage about MRUS stock has been trending negative on Tuesday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Merus earned a daily sentiment score of -2.4 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the company's share price in the next several days.
Who are some of Merus' key competitors?
Some companies that are related to Merus include Clovis Oncology (CLVS), Kiniksa Pharmaceuticals (KNSA), Apellis Pharmaceuticals (APLS), Uniqure (QURE), Deciphera Pharmaceuticals (DCPH), Retrophin (RTRX), Rhythm Pharmaceuticals (RYTM), Amphastar Pharmaceuticals (AMPH), TherapeuticsMD (TXMD), Homology Medicines (FIXX), Puma Biotechnology (PBYI), Crinetics Pharmaceuticals (CRNX), Athenex (ATNX), ImmunoGen (IMGN) and Lexicon Pharmaceuticals (LXRX).
Who are Merus' key executives?
Merus' management team includes the folowing people:
- Dr. Ton Logtenberg Ph.D., Co-Founder, CEO & Exec. Director (Age 60)
- Dr. Hennie Hoogenboom Ph.D., Co-Founder and Scientific Advisor
- Mr. John J. Crowley, CFO & Exec. VP (Age 44)
- Ms. Jillian Connell, VP of Investor Relations & Corp. Communications
- Mr. John de Kruif Ph.D., CTO & Sr. VP
When did Merus IPO?
(MRUS) raised $64 million in an initial public offering on Thursday, May 19th 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. Citigroup and Jefferies served as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.
Who are Merus' major shareholders?
Merus' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Aquilo Capital Management LLC (5.73%), Laurion Capital Management LP (0.47%), Morgan Stanley (0.32%), Stanley Laman Group Ltd. (0.19%), Acadian Asset Management LLC (0.12%) and Renaissance Technologies LLC (0.11%).
Which institutional investors are selling Merus stock?
MRUS stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and Stanley Laman Group Ltd..
Which institutional investors are buying Merus stock?
MRUS stock was bought by a variety of institutional investors in the last quarter, including Laurion Capital Management LP, Aquilo Capital Management LLC, Morgan Stanley, Acadian Asset Management LLC and JPMorgan Chase & Co..
How do I buy shares of Merus?
Shares of MRUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Merus' stock price today?
One share of MRUS stock can currently be purchased for approximately $12.27.
How big of a company is Merus?
Merus has a market capitalization of $281.90 million and generates $15.36 million in revenue each year. The biotechnology company earns $-82,610,000.00 in net income (profit) each year or ($4.29) on an earnings per share basis. Merus employs 83 workers across the globe.
What is Merus' official website?
How can I contact Merus?
Merus' mailing address is YALELAAN 62, UTRECHT P7, 3584 CM. The biotechnology company can be reached via phone at 31-0-30-253-8800 or via email at [email protected]
MarketBeat Community Rating for Merus (NASDAQ MRUS)
MarketBeat's community ratings are surveys of what our community members think about Merus and other stocks. Vote "Outperform" if you believe MRUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
